FdaApplication
BLA 125249
Identifiers
- fda_app_no: BLA125249
Properties
| Property | Value |
|---|---|
| applicant_name | Kiniksa Pharmaceuticals (UK), Ltd. |
| application_type | BLA |
| approval_date | 2008-02-27 |
Revenue by product
ARCALYST
| Period | Revenue |
|---|---|
| Q2 2026 | $243.6M |
| Q1 2026 | $214.3M |
| Q3 2025 | $180.9M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ARCALYST | RILONACEPT | 220MG | VIAL;SINGLE-USE |
1 product